Brief: Cellares, Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201
06/11/2023 13:20
Nov 6 (Reuters) - Cabaletta Bio Inc CABA.O :
* CELLARES AND CABALETTA BIO PARTNER TO EVALUATE AUTOMATED
MANUFACTURING FOR CABA-201, CABALETTA’S CD19-CAR T CELL THERAPY
ON CELLARES’ CELL SHUTTLE PLATFORM
* CABALETTA BIO INC: COLLABORATION WITH INTENT TO VALIDATE
CELLARES' CELL SHUTTLE PLATFORM FOR MANUFACTURING OF CABA-201
Source text for Eikon: ID:nBw5nScLba
Further company coverage: CABA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cabaletta Bio
See all newsCabaletta Bio Q1 net loss widens as R&D costs rise
Brief: First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform
Brief: IND Amendment Clearance Obtained For Clinical Manufacturing Of Rese-Cel From Cabaletta Bio Using Cellares' Automated Platforms
Cabaletta Bio reports smaller-than-expected Q3 loss
U.S. RESEARCH ROUNDUP-Beacon Financial, Comerica, Doximity